ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0731

Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U

Jackeline Rodriguez-Smith1, Virginia Miraldi Utz2, Amy Cassedy1, Sherry Thornton1, Grant Schulert3, Alyssa Sproles4, Najima Mwase1, Theresa Hennard1, Mekibib Altaye2, Alexei Grom1 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati

Meeting: ACR Convergence 2020

Keywords: Biomarkers, cytokines, Eye Disorders, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Pediatric Rheumatology – Clinical Poster II: JIA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of uveitis activity. AqH collection is invasive and less feasible. Tears may serve as a surrogate as the same biomarkers present in AqH were detected in tears of uveitis patients. We showed that S100A12, IL-8, and sICAM-1 levels differ based on uveitis activity in JIA-associated uveitis (JIA-U). We aim to determine if tear-based biomarkers differ in a patient’s eyes based on uveitis activity by laterality and diagnoses.

Methods: Tears were collected by Schirmer strips from children ≥5 years old with diagnosis of bilateral uveitis. Uveitis activity was graded by SUN criteria. Anterior chamber (AC) cell grade < 0.5 was inactive. AC grades ≥0.5+ were active. S100A8, A9 and A12 were measured by ELISA, and IL-18, IL-8, IP-10, MCP-1, RANTES and sICAM-1 by Luminex assays. Biomarkers levels were assessed between paired eyes of a person by 1) unilateral activity (active eye and inactive contralateral eye), 2) bilateral activity (both active eyes), and 3) diagnosis (JIA-U vs non-JIA-U).

Results: Fifteen children contributed 34 tear samples (JIA-U n=8; idiopathic chronic anterior uveitis n=5; and idiopathic uveitis n=2). At time of tear collection, 53% had bilateral active uveitis (53% AC cell grade 0.5+). Treatment included topical (82%) and systemic therapy (76%) (Table 1). Stratifying by laterality, all biomarker levels were similar between the active uveitic eye and the inactive contralateral uveitic eye in those with unilateral active uveitis. In bilateral active uveitis, levels were also similar in both eyes except for S100A12 that was lower in the higher-grade uveitic eye (7979 pg/ML-/+SD 7835) compared to the lower-grade (25,727+/- 39,154; P=0.032). Stratifying by diagnosis, children with JIA-U relative to non-JIA-U group, primarily had unilateral active uveitis (78 vs 25%) with AC cell grade 0.5+ (100 vs 53%), greater use of systemic therapy (89 vs 63%) with similar use of topical steroids (83 vs 81%). Regardless of uveitis activity, biomarkers levels between both eyes of children with JIA-U were similar. In non-JIA-U, only S100A12 was higher in the lower-grade or inactive eye. All other biomarkers levels were similar. Comparing eyes of children with JIA-U and non-JIA-U, the JIA-U group had significantly higher S100A12, IL-8, RANTES, and sICAM than non-JIA-U (Table 2).

Conclusion: Our results suggest that S100A12 levels may differ in the eyes of children with a history of bilateral uveitis who have bilateral active disease especially non-JIA-U. Although we expected a difference in biomarker levels of paired eyes of children with unilateral active uveitis, earlier damage to the blood-ocular barrier may allow crossing of biomarkers to the inactive uveitic eye. Use of topical steroids may also dampen the inflammatory response. Elevated S100A12, sICAM, and IL-8 in children with JIA-U compared to non-JIA-U supports the potential role of neutrophils in JIA-U. A limitation of our study is sample size. Further work is needed to clarify the impact of topical steroids on biomarkers levels and the role of S100A12, sICAM1, and IL-8 in uveitis activity.

Table 1: Clinical characteristics

Table 2: Tear biomarker levels between JIA-U and non-JIA-U


Disclosure: J. Rodriguez-Smith, None; V. Miraldi Utz, None; A. Cassedy, None; S. Thornton, None; G. Schulert, Novartis, 5, Sobi, 5; A. Sproles, None; N. Mwase, None; T. Hennard, None; M. Altaye, None; A. Grom, Sobi, Novartis and AB2Bio, 5; S. Angeles-Han, Nation Institutes of Health, 2, Emory University, 7, Knights Templar Eye Foundation, 2, Emory University, 2.

To cite this abstract in AMA style:

Rodriguez-Smith J, Miraldi Utz V, Cassedy A, Thornton S, Schulert G, Sproles A, Mwase N, Hennard T, Altaye M, Grom A, Angeles-Han S. Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/comparing-s100-proteins-and-cytokine-levels-in-tears-based-on-uveitis-activity-laterality-in-children-with-jia-associated-uveitis-and-non-jia-u/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-s100-proteins-and-cytokine-levels-in-tears-based-on-uveitis-activity-laterality-in-children-with-jia-associated-uveitis-and-non-jia-u/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology